-+ 0.00%
-+ 0.00%
-+ 0.00%
Akebia Therapeutics Wins US Patent for Vafseo With Term Through 2043
Share
Listen to the news
Akebia Therapeutics Wins US Patent for Vafseo With Term Through 2043
  • Akebia Therapeutics received a U.S. patent for Vafseo (vadadustat), with a term through January 18, 2043.
  • The patent covers methods for managing drug-drug interactions during vadadustat treatment; it is eligible for Orange Book listing.
  • Fourteen other vadadustat patents are listed in the Orange Book, with expiration dates between 2027 and 2036.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171605PRIMZONEFULLFEED9879828) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending